



ASX release

14 March 2018

AtCor Announces First Steps in Major Strategic Repositioning

AtCor Medical Holdings Limited (ASX: ACG) today announced the first steps in a major repositioning of the company as a global health technology provider including:

1. **A proposal to change the name of the company** (subject to shareholder approval) to **CardieX Limited** – a name that recognises AtCor’s legacy in cardiovascular health while at the same time promoting excellence and expertise in global health solutions. The name change is part of a complete re-branding of the company currently being implemented by executive management.
2. The execution of a **Development and Collaboration Agreement with Blumio, Inc**, a Silicon Valley based developer of sensor and wearable technology for blood pressure detection. This agreement provides the framework for the development and integration of AtCor’s IP and patents into Blumio’s sensors and the collaboration of the parties in developing new technology applications for sensor-based detection of cardiovascular disease.
3. **The execution of an agreement between Blumio and AtCor for a potential investment by AtCor in Blumio of up to USD\$600K** (subject to certain capital raise, due diligence and other conditions) that will allow AtCor to obtain up to a 7.5% equity shareholding in Blumio, Inc. Blumio’s current investors include Facebook investor and PayPal founder Peter Thiel (through his Thiel Foundation - which backs innovative companies with significant technology solutions).

Craig Cooper, AtCor’s CEO, said “As we position the company for growth, it’s important that we partner and align ourselves with world-class companies at the cutting edge of technology and innovation. Our partnership and investment in Blumio will position us at the centre of excellence in Silicon Valley and allow us to leverage our IP and patents into new wearable and consumer platforms. This is a significant move forward for AtCor and represents the first step in our plan to become the world leader in hypertension and cardiovascular health.”

Further details of the above will be released shortly to the ASX including an investor presentation and details of a proposed Extraordinary General Meeting (EGM) to approve any resolutions related to the above.

About AtCor Medical

AtCor Medical develops and markets products for large-scale population health disorders with a focus on cardiovascular disease.

*For further information, please contact
(AtCor):*

Craig Cooper – CEO
+61 429 993 399

Donal O’Dwyer – Chairman
+61 (2) 9874 8761

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or
a.rambukwella@fcr.com.au

For personal use only